Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPRGO
āļāļ·āđāļāļāļĢāļīāļĐāļąāļPerrigo Company PLC
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļDec 17, 1991
āļāļĩāļāļĩāđāļLockwood-Taylor (Patrick)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ8379
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļDec 17
āļāļĩāđāļāļĒāļđāđThe Sharp Building
āđāļĄāļ·āļāļDUBLIN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻIreland
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđD02 TY74
āđāļāļĢāļĻāļąāļāļāđ3532696738451
āđāļ§āđāļāđāļāļāđhttps://www.perrigo.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPRGO
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļDec 17, 1991
āļāļĩāļāļĩāđāļLockwood-Taylor (Patrick)
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Mr. Donal O'Connor
Independent Director
Ms. Adriana (Andi) Karaboutis
Ms. Adriana (Andi) Karaboutis
Independent Director
Mr. Orlando D. Ashford
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Ms. Julia M. Brown
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Mr. Donal O'Connor
Independent Director
Sound Equity Dividend Income ETF
State Street SPDR S&P Pharmaceuticals ETF
Invesco Pharmaceuticals ETF
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
ProShares S&P MidCap 400 Dividend Aristocrats ETF
First Trust Health Care Alphadex Fund
Invesco S&P MidCap 400 Pure Value ETF
Invesco High Yield Equity Dividend Achievers ETF
iShares U.S. Pharmaceuticals ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Sound Equity Dividend Income ETF
āļŠāļąāļāļŠāđāļ§āļ3.3%
State Street SPDR S&P Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ2.44%
Invesco Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ2.34%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
āļŠāļąāļāļŠāđāļ§āļ1.54%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
āļŠāļąāļāļŠāđāļ§āļ1.35%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
āļŠāļąāļāļŠāđāļ§āļ1.32%
First Trust Health Care Alphadex Fund
āļŠāļąāļāļŠāđāļ§āļ1.22%
Invesco S&P MidCap 400 Pure Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.19%
Invesco High Yield Equity Dividend Achievers ETF
āļŠāļąāļāļŠāđāļ§āļ1.11%
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ1.05%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
574.20M
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Mar 24, 2026 going ex on Mar 02, 2026
PRGO.NB Final Cash Dividend of gross USD 0.29 paid on Dec 16, 2025 going ex on Nov 28, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Sep 16, 2025 going ex on Aug 29, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Jun 17, 2025 going ex on May 30, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Mar 25, 2025 going ex on Mar 07, 2025
PRGO.NB Final Cash Dividend of gross USD 0.276 paid on Dec 17, 2024 going ex on Nov 29, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Sep 17, 2024 going ex on Aug 30, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Jun 18, 2024 going ex on May 31, 2024
PRGO.NB Interim Cash Dividend of gross USD 1.1 paid on Mar 26, 2024 going ex on Mar 07, 2024
PRGO.NB Final Cash Dividend of gross USD 0.273 paid on Dec 19, 2023 going ex on Nov 30, 2023
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ